To the Editor:
We read with great interest the article entitled "Paranuclear Dot-Like Immunostaining for CD99: A Unique Staining Pattern for Diagnosing SolidPseudopapillary Neoplasm of the Pancreas" authored by Dr Xiao and colleagues.
1 The authors describe a unique paranuclear dot-like immunoreactivity for CD99 in neoplastic epithelial cells of solid-pseudopapillary neoplasms of the pancreas, which is different from the expected cellular immunolocalization along the cell membrane, indicative of intercellular cohesive signaling. The authors use this unique immunostaining pattern to distinguish solid-pseudopapillary neoplasms from other pancreatic solid tumors.
The authors state that this staining pattern has not been recognized in other tumor types. We wish to report that, in a study of colon cancer carcinogenesis and progression, we have identified an identical dot-like intracellular paranuclear immunoreactivity both in colonic adenomas and in their adjacent colonic adenocarcinomas in 30 cases of invasive adenocarcinomas assayed for CD99 (polyclonal, Abcam, ab27271) immunoreactivity (Figs. 1, 2 ). Similar to their findings, the granular dot-like immunoreactivity in our cases appears intracytoplasmic, adjacent to the nucleus, and as supranuclear (between the nucleus and the apical membrane) cellular immunolocalization within columnar tumor cells. A minority of cases also demonstrated expected cytoplasmic membrane staining in addition to the dot-like paranuclear expression. We have not, as yet, assayed the cellular immunoreactive localization of CD99 in other adenocarcinomas.
The granular pattern of immunoreactivity may represent localization to Golgi apparatus, rough endoplasmic reticulum, or amorphous intracellular deposition of CD99 immunoreactive peptide. Demonstrating CD99 dot-like immunoreactivity in adenomas and adenocarcinomas suggests that the anomalous immunocellular localization is an early event in colonic carcinogenesis. The molecular event, corresponding to granular dotlike paranuclear immunoreactivity, may indicate a defective CD99 protein incapable of membrane localization, absent or abnormal signal polypeptide, or a unique protein with shared CD99 epitopes or antigenic sites.
We agree with Dr Xiao and colleagues that intracellular paranuclear dot-like CD99 immunoreactivity may serve as an immunohistochemical feature in the differential diagnosis of pancreatic solid tumors, and, in addition, may provide insight into cellular mechanisms of tumor initiation and progression in colonic adenocarcinomas. type (WT) for KIT and Alpha-type platelet-derived growth factor receptor (PDGFRA) mutations (KIT/PDGFRA WT). Clinically, the tumors often give rise to lymph node metastases, both at the time of diagnosis or as sites of distant recurrence. None of the patients showed a radiologic response to imatinib; 2 patients showed a response to sunitinib, and most of them experienced an indolent clinical course.
As is well known, about 10% to 15% of adult GISTs are KIT/ PDGFRA WT and differ from mutant GISTs in clinical behavior and underlying genomic background, representing a distinct molecular subtype of GIST. 2, 4, 7, 13 However, the clinical outcome is heterogenous also among adult KIT/PDGFRA WT GIST patients, suggesting a small group with disease different from conventional adult KIT/PDGFRA WT GIST. Rege et al 11 drew attention to "adult" GIST patients with the same histologic and clinical features as "pediatric" GIST patients sharing the absence of KIT and PDGFRA gene mutations. To date, the oncogenic defects responsible for the development of this type of disease have not been identified. We are contributing to the interesting topic highlighted by Rege et al 11 in 2 ways: reporting our experience with 4 nonsyndromic adult GIST patients with pediatric characteristics and discussing the opportunity to explore the genomic background further, focusing particularly on succinate dehydrogenase complex (subunits A, B, C, and D) mutations.
We report the data from 4 patients with a GIST localized in the stomach, which was multifocal in 2 patients, with a female predominance (3 patients out 4) and an indolent course even if metastatic (3 patients). The sites of metastases were liver and lymph nodes in 2 patients and liver, lymph nodes, and lung in 1 patient, with histologic confirmation of all sites of metastases (Table 1) . Three primary tumors had a mixed morphology of spindle and epithelioid cells, and 1 had epithelioid cells with dimension ranging between 6 and 10.5 cm and a mitotic rate ranging from 1 to 10/50 high-power fields.
Three tumors were classified as having high risk of recurrence according to the Miettinen Classification. The largest tumor from patient 4 had a low risk of metastatic recurrence according to the Miettinen Classification and intermediate risk according to the Fletcher Classification. However, after 13 years, the patient presented with novel lesions (dimension between 1.6 and 4.5 cm) in the stomach. Some of them were probably new primary tumors, confirmed as GIST at biopsies because they arose far from the site of the primary tumor resection, and 1 lesion was probably local recurrence because it arose at the same previous site even if it could not be confirmed or excluded. All 4 tumors were positive for KIT, whereas 3 of 4 showed immunoreactivity for CD34. DOG1 was available in only 2 cases and was positive. Two tumors were weakly positive for smooth muscle actin. None was positive for S-100 protein or desmin. None of the GISTs harbored any KIT or PDGFRA gene mutations.
Two patients (1 and 3) received imatinib for metastatic disease and then experienced a prolonged disease stabilization under sunitinib treatment. Patient 2 was operated upon for primary GIST, liver, and lymph node metastases up front and received imatinib in the adjuvant setting. The last patient (patient 4) did not receive imatinib treatment; she only underwent resection of primary GIST (classified as low risk of metastatic recurrence). No data are available on the follow-up treatment of the recent new lesions.
All 4 of our patients harbor mutations in succinate dehydrogenase complex, subunit A (SDHA) (Fig. 1) . SDHA mutations in 2 of them were identified using a massively parallel sequencing approach and were reported in a previous article.
8 Both of these cases have already been reported, and the 2 new ones described here were completely resequenced by conventional Sanger sequencing using specific primer pairs designed to amplify each of the 15 exons of SDHA gene without amplifying the pseudogenes located on chromosomes 3 and 5. Patient 1 was homozygous for a
